What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature that provides access to the same valuation methodology used by Fundamental Research Corp for allocating our firm's capital. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is Innovent Biologics, Inc. stock price today?

Innovent Biologics, Inc. (IVBXF) is currently trading at $12.32 USD on OTC. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does Innovent Biologics, Inc. do?

Innovent Biologics, Inc. operates in the Biotechnology sector within Healthcare. Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-...

How do I analyze Innovent Biologics, Inc. stock performance?

Our Snowflake Analysis provides a visual snapshot of Innovent Biologics, Inc. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find Innovent Biologics, Inc. financial statements?

Access Innovent Biologics, Inc. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC uses the same proprietary valuation model for public stock analysis that we use for allocating our own firm's capital. This means our fair value estimates are based on the same rigorous, data-driven methodology that institutional investors trust. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About Innovent Biologics, Inc.

Industry

Biotechnology

Sector

Healthcare

CEO

De-Chao Yu

Headquarters

168 Dongping Street, Suzhou, CN

Industry

Biotechnology

Sector

Healthcare

CEO

De-Chao Yu

Headquarters

168 Dongping Street, Suzhou, CN

Description

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Innovent Biologics, Inc.

IVBXF•OTC

Innovent Biologics, Inc.

IVBXF•OTC

Market cap

$19.41B

Sentiment

Your view on IVBXF

Mkt Cap

$19.41B

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About Innovent Biologics, Inc.

Industry: Biotechnology
Sector: Healthcare
CEO: De-Chao Yu
Headquarters: 168 Dongping Street, Suzhou, CN

Industry: Biotechnology
Sector: Healthcare
CEO: De-Chao Yu
Headquarters: 168 Dongping Street, Suzhou, CN

Description

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News